Community dentists can play a key role in the prevention and diagnosis of osteonecrosis of the jaw (ONJ) in patients receiving antiresorptive agents
ONJ is a rare complication that can be associated with the use of bone-protecting (antiresporptive) agents that are used for patients with cancer and bone metastases.
Learn more here about the signs and symptoms of ONJ and approaches to manage this condition.
Download leaflet for Clinicians in:
Download leaflet for Dentists in:
Other downloads:
The content of this page has been sponsored by Amgen.
Amgen has grown to be one of the world's leading independent biotechnology companies that focuses on areas of high unmet medical need and strives for solutions that improve health outcomes and dramatically improve peoples’ lives.
AMGEN Videos
Advice for clinicians |
|
Handling patient questions about ONJ |
|
ONJ and bone-targeted agents |
|
What is ONJ and who is at risk |
